Unleashing unconventional antigens for cancer immunotherapy
The Enara Bio® purpose
Shining a light on Dark Antigen® and T-cell biology to enable people to live free from the shadow of cancer.
Our mission is to exploit previously uncharted genomic dark matter to develop cancer immunotherapies that deliver transformative benefit for broad patient populations.
To achieve our mission, we have built two innovative technology platforms:
EDAPT® pipeline that enables us to discover and validate a novel class of cancer-specific antigens derived from the genomic dark matter, which we call Dark Antigens.
EnTiCE® platform for optimizing proprietary bispecific T-cell engagers to deliver best-in-class treatments for solid tumors.
We are rapidly advancing our lead program to the clinic, a bispecific T-cell engager that targets a previously undiscovered antigen that we have named DARKFOX™.
Who we are
We are a diverse, experienced, and rapidly growing team driven by a common purpose and united by our shared values. The culture we have developed enables each of us to make an impact and deliver on our vision.
Featured news
-
Enara Bio to Reveal DARKFOX, a Novel Cancer-Specific Dark Antigen with Broad-Ranging Therapeutic Potential, in Oral Presentation at SITC 2025
Enara Bio, a biopharmaceutical company pioneering the discovery of novel Dark Antigens® and the development of bispecific T cell engagers for solid tumors, will present two abstracts related to the significant therapeutic potential of DARKFOXTM at the upcoming 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
-
Boehringer Ingelheim licenses multiple Dark Antigens® from Enara Bio to develop off-the-shelf immunotherapies for non-small cell lung cancer (NSCLC)
Licensed antigens are shared across major subsets of NSCLC and have confirmed presence on the surface of tumor cells, homogeneous expression within tumors, and strong immunogenicity